DS
Deepkumar Shantibhai Vanecha
About Deepkumar Shantibhai Vanecha
Deepkumar Shantibhai Vanecha has 2 years in corporate governance. Holds Director and Designated Partner roles. Currently with 1 company, including Genaide Pharmaceutical Private Limited and Genaide Pharmaceutical Llp. Formerly with 2 companies, such as Exylone Lifescience Private Limited. Engaged in General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Genaide Pharmaceutical Private Limited
U46497GJ2025PTC160471
|
Director | 20 Mar 2025 | 2025 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Exylone Lifescience Private Limited
U51391GJ2022PTC129435
|
Additional Director | 30 Jan 2025 | 2022 | Active |
Genaide Pharmaceutical Llp
AAH-8284
|
Designated Partner | 25 Sep 2023 | 2016 | Converted And Dissolved |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Deepkumar Shantibhai Vanecha
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Deepkumar Shantibhai Vanecha
Deepkumar Shantibhai Vanecha has 2 years in corporate governance. Holds Director and Designated Partner roles. Currently with 1 company, including Genaide Pharmaceutical Private Limited and Genaide Pharmaceutical Llp. Formerly with 2 companies, such as Exylone Lifescience Private Limited. Engaged in General Business. Contributes to corporate operations.
Deepkumar Shantibhai Vanecha is associated with 1 company as Director and Designated Partner.
Deepkumar Shantibhai Vanecha has expertise in General Business.
Deepkumar Shantibhai Vanecha has 2 years in corporate governance.